Search

Your search keyword '"Doz F"' showing total 45 results

Search Constraints

Start Over You searched for: Author "Doz F" Remove constraint Author: "Doz F" Topic medulloblastoma Remove constraint Topic: medulloblastoma
45 results on '"Doz F"'

Search Results

2. Neurocognitive and radiological follow-up of children under 5 years of age treated for medulloblastoma according to the HIT-SKK protocol.

3. Failure of human rhombic lip differentiation underlies medulloblastoma formation.

4. Current treatments of medulloblastoma.

5. Medulloblastomas associated with an APC germline pathogenic variant share the good prognosis of CTNNB1-mutated medulloblastomas.

6. An autocrine ActivinB mechanism drives TGFβ/Activin signaling in Group 3 medulloblastoma.

7. SHH medulloblastoma in a young adult with a TCF4 germline pathogenic variation.

8. Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial.

9. Hippocampal Sparing During Craniospinal Irradiation: What Did We Learn About the Incidence of Perihippocampus Metastases?

10. NRL and CRX Define Photoreceptor Identity and Reveal Subgroup-Specific Dependencies in Medulloblastoma.

11. Minimal methylation classifier (MIMIC): A novel method for derivation and rapid diagnostic detection of disease-associated DNA methylation signatures.

12. Relapse patterns and outcome after relapse in standard risk medulloblastoma: a report from the HIT-SIOP-PNET4 study.

13. Risk stratification of childhood medulloblastoma in the molecular era: the current consensus.

14. Biomarker-driven stratification of disease-risk in non-metastatic medulloblastoma: Results from the multi-center HIT-SIOP-PNET4 clinical trial.

15. Neuropsychological Outcome of Children Treated for Standard Risk Medulloblastoma in the PNET4 European Randomized Controlled Trial of Hyperfractionated Versus Standard Radiation Therapy and Maintenance Chemotherapy.

16. A five-gene hedgehog signature developed as a patient preselection tool for hedgehog inhibitor therapy in medulloblastoma.

17. Chemotherapy for children with medulloblastoma.

18. Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition.

19. Medulloblastoma Down Under 2013: a report from the third annual meeting of the International Medulloblastoma Working Group.

20. Quality of survival and growth in children and young adults in the PNET4 European controlled trial of hyperfractionated versus conventional radiation therapy for standard-risk medulloblastoma.

21. MYC and MYCN amplification can be reliably assessed by aCGH in medulloblastoma.

22. Hyperfractionated versus conventional radiotherapy followed by chemotherapy in standard-risk medulloblastoma: results from the randomized multicenter HIT-SIOP PNET 4 trial.

24. Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas.

25. Interval between onset of symptoms and diagnosis of medulloblastoma in children: distribution and determinants in a population-based study.

26. Long time to diagnosis of medulloblastoma in children is not associated with decreased survival or with worse neurological outcome.

27. Medulloblastomas: update on a heterogeneous disease.

28. Inhibin B and anti-Müllerian hormone as markers of gonadal function after treatment for medulloblastoma or posterior fossa ependymoma during childhood.

29. [Medulloblastomas: review].

30. From childhood to adulthood: long-term outcome of medulloblastoma patients. The Institut Curie experience (1980-2000).

31. Beta-catenin status in paediatric medulloblastomas: correlation of immunohistochemical expression with mutational status, genetic profiles, and clinical characteristics.

32. [Childhood medulloblastoma].

33. High-dose chemotherapy with autologous stem cell rescue followed by posterior fossa irradiation for local medulloblastoma recurrence or progression after conventional chemotherapy.

34. Treatment of high risk medulloblastomas in children above the age of 3 years: a SFOP study.

35. Treatment of medulloblastoma with postoperative chemotherapy alone: an SFOP prospective trial in young children.

36. Standard-risk medulloblastoma treated by adjuvant chemotherapy followed by reduced-dose craniospinal radiation therapy: a French Society of Pediatric Oncology Study.

37. Impact of targeting deviations on outcome in medulloblastoma: study of the French Society of Pediatric Oncology (SFOP).

38. Improving survival in recurrent medulloblastoma: earlier detection, better treatment or still an impasse?

39. [High-dose chemotherapy in relapse of medulloblastoma in young children].

40. Will high dose chemotherapy followed by autologous bone marrow transplantation supplant cranio-spinal irradiation in young children treated for medulloblastoma?

41. Preirradiation chemotherapy including "eight drugs in 1 day" regimen and high-dose methotrexate in childhood medulloblastoma: results of the M7 French Cooperative Study.

42. Metastatic medulloblastoma: the experience of the French Cooperative M7 Group.

43. Carboplatin and VP 16 in medulloblastoma: a phase II Study of the French Society of Pediatric Oncology (SFOP).

44. [Malignant cerebral tumors in children].

45. Le médulloblastome de l’enfant

Catalog

Books, media, physical & digital resources